Introduction
The characterization of atherosclerotic plaque and its propensity to rupture remains one of the principal challenges in cardiovascular medicine. Although MRI of atheromatous plaques with endogenous contrast mechanisms remains of signifi cant value, additional information regarding plaque composition and metabolic activity is needed to fully characterize a plaque and its propensity to rupture. Molecular MRI provides this additional information by imaging the cellular and molecular characteristics of atheromatous plaque, in a noninvasive, quantifi able, and serial manner. In this brief review we highlight recent advances in molecular MRI of atherosclerotic plaque. The interested reader is referred to several detailed articles for a more comprehensive and longitudinal review of the fi eld [1, 2] .
Molecular magnetic resonance contrast agents can be broadly divided into two categories: paramagnetic gadolinium (Gd)-based agents and superparamagnetic (iron-oxide) nanoparticles. The ability of these agents to image aspects of plaque biology, including the expression of endothelial adhesion molecules [3••] , plaque lipid and macrophage content [4••,5••], angiogenesis [6] , and plaque thrombosis [7] , has been demonstrated in mice, in large animal models, and more recently in humans [8,9,10••] . Molecular MRI provides high-resolution images of these key molecular processes in atherosclerotic plaque, allowing integrated anatomical, physiological, and molecular imaging to be performed in a single comprehensive and integrated dataset. The recent development of integrated magnetic resonance-positron emission tomography (PET) scanners also raises the possibility of dual modality imaging, exploiting the strengths of both PET-and MR-based molecular imaging.
Gadolinium-Based Agents
There has been considerable effort to use Gd-based probes to target specifi c plaque components. Gd offers the benefi t of positive image contrast on T1-weighted images. The majority of work to date has been preclinical, with the exception of the fi brin-targeted probe EP-2104R, for which limited data in humans have been reported [10••] . Contrast agents targeted to the α v β 3 integrin [6], fi brin [7, 11, 12] [20, 21] , and Gd linked to long-chain fatty acids [15] , have also shown plaque enhancement in mouse and rabbit models of atherosclerosis. Even conventional Gd-DTPA has been shown to enhance vessel wall in atherosclerotic lesions under delayed contrast enhancement techniques [22] . It is hoped, however, that the molecular specifi city of the targeted agents will inform not only on the presence of the plaque but also its stage and its risk for rupture.
There are basically two platforms for Gd-based plaque agents (Fig. 1) . The fi rst is a discrete small-to medium-sized molecule (< 10 kDa) comprising a plaque recognition element and one or more Gd-chelates. The benefi ts of this approach are 1) typically fast uptake into the plaque because of the small size of the agent; 2) fast blood clearance and renal excretion (this leads to good target:background at early time points as well as better elimination of the potentially toxic Gd metal ion); and 3) the discrete nature of the molecule enables reproducible manufacturing, which is a key feature for translation to the clinic. The major drawback of the small-molecule approach is that many molecular targets of interest are I Cardiac Magnetic Resonance present at too low a concentration (submicromolar) in plaque to be measurably enhanced by a few Gd chelates. This has necessitated a nanoparticle self-assembly approach in which 1000s of Gd-chelates provide signal enhancement and targeting is achieved by incorporation of some recognition element (eg, antibody, peptide) for the plaque component (Fig. 1) . In general, optimal image contrast may occur at hours to days postinjection because of slower targeting/elimination pharmacokinetics.
Fibrin targeting for advanced plaque
Rupture of an atheromatous plaque resulting in thrombosis is the accepted cause of most acute coronary syndromes and sudden cardiac death. Many atherosclerotic plaques do not limit fl ow but pose a great risk of an ischemic event, especially in asymptomatic patients. Such plaques may rupture or erode, creating a thrombogenic surface and subsequent thrombosis of the vessel or embolism [23] [24] [25] . The presence of fi brin is indicative of stage VI plaque, the most advanced state of disease. Because fi brin is not found in the vasculature outside of thrombi, it represents a useful target for identifying late-stage complex plaque.
Circulating fi brinogen is present in the 5-to 10-μM range. In the clotting cascade, fi brinogen is polymerized to fi brin, resulting in a localized fi brin monomer concentration in the 10s to 100s of μM. This high concentration is compatible with magnetic resonance detection using the targeted small-molecule approach. However, the fi rst targeted fi brin magnetic resonance probe was based on a self-assembled particle. Flacke et al.
[11] described a Gd-based nanoparticle targeted to fi brin via an antibody and demonstrated its efficacy in a canine venous thrombus model. Later, Botnar et al.
[7] described a fi brin-specifi c peptide derivatized with four Gd-DTPA units (termed EP-1873) that was used to identify thrombi in a rabbit model of plaque rupture. EP-2104R is a probe similar to EP-1873 but employs the more stable Gd-DOTA chelate. After evaluation in a number of preclinical rabbit [26] and swine models [27] [28] [29] [30] [31] , EP-2104R advanced to human studies (Fig. 2) . EP-2104R binds equally to two sites on human fi brin (K d = 1.7 μΜ), with excellent specifi city for fi brin over fi brinogen (over 100-fold) and for fi brin over serum albumin (over 1000-fold) [12] . The relaxivity of EP-2104R bound to fi brin at 37° C and 1.4 T was 71.4 mM-1 s-1 per molecule of EP-2104R (17.4 per Gd), about 25 times higher than that of Gd-DOTA measured under the same conditions [12] .
In a clinical trial, EP-2104R was evaluated for detection of thrombus in six territories: the deep veins, pulmonary Figure 1 . Platforms for gadolinium (Gd)-based plaque agents. One strategy, shown on the right, involves the synthesis of a discrete small-to medium-sized molecule (< 10 kDa) comprising a plaque recognition element and one or more Gd-chelates. The second strategy involves nanoparticle self-assembly, in which 1000s of Gd-chelates provide signal enhancement, and targeting is achieved by incorporation of a recognition element (eg, antibody, peptide) for the plaque component. Additional components can be added for fl uorescence detection and/or pharmacokinetic modifi cation. PEG-polyethylene glycol.
